Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

524 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
Ruggiero CF, Fattore L, Terrenato I, Sperati F, Salvati V, Madonna G, Capone M, Valenti F, Di Martino S, Mandoj C, Liguoro D, Castaldo V, Cafaro G, Simeone E, Vanella V, Russillo M, Conti L, Cuda G, Giannarelli D, Ascierto PA, Mancini R, Ciliberto G. Ruggiero CF, et al. Among authors: ciliberto g. Theranostics. 2022 Oct 24;12(17):7420-7430. doi: 10.7150/thno.77761. eCollection 2022. Theranostics. 2022. PMID: 36438490 Free PMC article.
Targeting the MITF/APAF-1 axis as salvage therapy for MAPK inhibitors in resistant melanoma.
Carotenuto P, Romano A, Barbato A, Quadrano P, Brillante S, Volpe M, Ferrante L, Tammaro R, Morleo M, De Cegli R, Iuliano A, Testa M, Andreone F, Ciliberto G, Clery E, Troncone G, Palma G, Arra C, Barbieri A, Capone M, Madonna G, Ascierto PA, Lanfrancone L, Indrieri A, Franco B. Carotenuto P, et al. Among authors: ciliberto g. Cell Rep. 2022 Nov 8;41(6):111601. doi: 10.1016/j.celrep.2022.111601. Cell Rep. 2022. PMID: 36351409 Free article.
B4GALT1 as a New Biomarker of Idiopathic Pulmonary Fibrosis.
De Vitis C, D'Ascanio M, Sacconi A, Pizzirusso D, Salvati V, Mancini M, Scafetta G, Cirombella R, Ascenzi F, Bruschini S, Esposito A, Castelli S, Salvucci C, Teodonio L, Sposato B, Catizone A, Di Napoli A, Vecchione A, Ciliberto G, Sciacchitano S, Ricci A, Mancini R. De Vitis C, et al. Among authors: ciliberto g. Int J Mol Sci. 2022 Nov 30;23(23):15040. doi: 10.3390/ijms232315040. Int J Mol Sci. 2022. PMID: 36499368 Free PMC article.
Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration.
Krasniqi E, Goeman F, Pulito C, Palcau AC, Ciuffreda L, Di Lisa FS, Filomeno L, Barba M, Pizzuti L, Cappuzzo F, Sanguineti G, Maugeri-Saccà M, Ciliberto G, Fanciulli M, Blandino G, Vici P. Krasniqi E, et al. Among authors: ciliberto g. Int J Mol Sci. 2022 Nov 22;23(23):14534. doi: 10.3390/ijms232314534. Int J Mol Sci. 2022. PMID: 36498861 Free PMC article. Review.
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.
Scalera S, Ricciuti B, Mazzotta M, Calonaci N, Alessi JV, Cipriani L, Bon G, Messina B, Lamberti G, Di Federico A, Pecci F, Milite S, Krasniqi E, Barba M, Vici P, Vecchione A, De Nicola F, Ciuffreda L, Goeman F, Fanciulli M, Buglioni S, Pescarmona E, Sharma B, Felt KD, Lindsay J, Rodig SJ, De Maria R, Caravagna G, Cappuzzo F, Ciliberto G, Awad MM, Maugeri-Saccà M. Scalera S, et al. Among authors: ciliberto g. Ann Oncol. 2023 Mar;34(3):275-288. doi: 10.1016/j.annonc.2022.12.002. Epub 2022 Dec 13. Ann Oncol. 2023. PMID: 36526124 Free article.
MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer.
Dinami R, Pompili L, Petti E, Porru M, D'Angelo C, Di Vito S, Rizzo A, Campani V, De Rosa G, Bruna A, Serra V, Mano M, Giacca M, Leonetti C, Ciliberto G, Tarsounas M, Stoppacciaro A, Schoeftner S, Biroccio A. Dinami R, et al. Among authors: ciliberto g. EMBO Mol Med. 2023 Jan 11;15(1):e16033. doi: 10.15252/emmm.202216033. Epub 2022 Nov 25. EMBO Mol Med. 2023. PMID: 36426578 Free PMC article.
Malignant meningioma mTOR mutated and precision medicine.
Villani V, Tanzilli A, Vidiri A, Giangaspero F, Ciliberto G, Olivi A, Pace A. Villani V, et al. Among authors: ciliberto g. Neurol Sci. 2023 Mar;44(3):1073-1075. doi: 10.1007/s10072-022-06575-x. Epub 2022 Dec 26. Neurol Sci. 2023. PMID: 36567410
Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study.
Di Cosimo S, Lupo-Stanghellini MT, Costantini M, Mantegazza R, Ciceri F, Salvarani C, Zinzani PL, Mantovani A, Ciliberto G, Uccelli A, Baldanti F, Apolone G, Delcuratolo S, Morrone A, Locatelli F, Agrati C, Silvestris N. Di Cosimo S, et al. Among authors: ciliberto g. Front Oncol. 2022 Oct 20;12:1002168. doi: 10.3389/fonc.2022.1002168. eCollection 2022. Front Oncol. 2022. PMID: 36338743 Free PMC article.
HER2 mutation as an emerging target in advanced breast cancer.
Bon G, Di Lisa FS, Filomeno L, Arcuri T, Krasniqi E, Pizzuti L, Barba M, Messina B, Schiavoni G, Sanguineti G, Botti C, Cappelli S, Pelle F, Cavicchi F, Puccica I, Costantini M, Perracchio L, Maugeri-Saccà M, Ciliberto G, Vici P. Bon G, et al. Among authors: ciliberto g. Cancer Sci. 2024 May 7. doi: 10.1111/cas.16148. Online ahead of print. Cancer Sci. 2024. PMID: 38715247 Free article. Review.
524 results